Henlius Biotech shrugs off Hong Kong disruption with $477M IPO bidChina’s Henlius Biotech has pressed go on a $477 million initial public offering (IPO) on the Hong Kong Share XHenlius Biotech shrugs off Hong Kong disruption with $477M IPO bidhttps://pharmaphorum.com/news/henlius-biotech-shrugs-off-hong-kong-disruption-with-477m-ipo-bid/
Hong Kong biotechs IPOs face lower valuations after Ascletis flopBiotechs taking an advantage of new Hong Kong exchange rules have been told to expect lower valuations, after Share XHong Kong biotechs IPOs face lower valuations after Ascletis flophttps://pharmaphorum.com/news/hong-kong-biotech-ipos-face-lower-valuations-after-ascletis-flop/
Regulatory timelines in the Asia-PacificSnapshot of clinical trial application processes in the region. Share XRegulatory timelines in the Asia-Pacifichttps://pharmaphorum.com/views-and-analysis/regulatory-timelines-asia-pacific/